LOGIN  |  REGISTER
C4 Therapeutics

Veradigm Payerpath™ Rated #1 End-to-End Revenue Cycle Management (RCM) Software

June 08, 2023 | Last Trade: US$9.36 2.55 37.44
  • Annual survey results reveal company receives top ranking in RCM setting for the second consecutive year

CHICAGO / Jun 08, 2023 / Business Wire / Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced that Black Book, a healthcare-centric market research and public opinion research and consulting company, has honored Veradigm Payerpath with the highest ranking in its End-to-End RCM Software Technology, Physician Practices & Ambulatory Facilities/Groups category for 2023.

Black Book conducted polls and surveys with healthcare executives and front-line users about their current technology and services partners and awarded top-performing vendors based on 18 key performance indicators of client experience, loyalty, and customer satisfaction.

Veradigm Payerpath is an end-to-end revenue cycle management suite of solutions built to assist organizations improve revenue, streamline communications with payers and patients, and boost practice profitability for practices of all sizes and specialties.

“Veradigm Payerpath seamlessly connects patients, providers, and payers via the Veradigm Network,” said Tom Langan, President and Chief Commercial Officer of Veradigm. “Veradigm is dedicated to helping streamline patient interactions and support providers as they take control of their revenue cycle. We are proud that Black Book and its survey participants have recognized the value Payerpath brings to the ambulatory market.”

About Veradigm®

Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit http://www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube

© 2023 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB